Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS-Reference-Cited by-同舟云学术

Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS

Published:2023-03-31 Issue:1 Volume:26 Page:463-472
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Valerio Maricela¹²³⁴^ORCID,Veintimilla Cristina¹^ORCID,Rodríguez Carmen²⁵^ORCID,de la Villa Sofía¹^ORCID,Sánchez-Somolinos Mar¹,Cerezales Mónica⁶^ORCID,Crespo Carlos⁶⁷^ORCID,Rodríguez Sara¹²^ORCID,Adán Iván¹,Chamorro Esther²⁵^ORCID,Rosselló Irantzu⁸^ORCID,Muñoz Patricia¹²³⁴^ORCID

Affiliation:

1. Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain

2. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

3. Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

4. Facultad de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Universidad Complutense de Madrid, Madrid, Spain

5. Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain

6. Axentiva Solutions S.L., Barcelona, Spain

7. Departamento de G.M estadística, Universidad de Barcelona, Barcelona, Spain

8. Angelini Pharma España, Barcelona, Spain

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2190704

Reference25 articles.

1. Epidemiology and microbiology of skin and soft tissue infections

2. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study;Garau J;Clin Microbiol Infect,2013

3. Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients

4. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – annual epidemiological report 2019AER for 2019. Stockholm; 2020.

5. European Medicines Agency. EPAR: Xydalba dalbavancin hydrochloride – Europa EU. 2017.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis;International Journal of Infectious Diseases;2024-01

2. Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel;International Journal of Antimicrobial Agents;2023-11

3. Dalbavancin in Bone and Joint Infections: A Systematic Review;Pharmaceuticals;2023-07-15

4. Understanding the laps and relapse process: in-depth interviews with individual who use methamphetamine;Substance Abuse Treatment, Prevention, and Policy;2023-07-07